Sclerotherapy after variceal hemorrhage in noncirrhotic portal fibrosis

Am J Gastroenterol. 1989 Oct;84(10):1235-8.

Abstract

Sixty patients with variceal bleeding due to noncirrhotic portal fibrosis were treated by repeated endoscopic injection sclerotherapy. During each session, the varices were injected with a mean volume of 14.4 ml of 1% polidocanol intravariceally. This decreased rebleeding, as evidenced by a reduction in mean bleeding risk factor and transfusion requirement. Difference between pre- and post-sclerotherapy parameters were significant (p less than 0.001). Variceal obliteration was achieved in 53 (88%) patients. The mean sclerotherapy sessions required for eradication were 8.43 (SD = 2.41). Minor complications related to the procedure occurred in 12% of patients. Cumulative survival for 5 yr was 86%. Survival was significantly related to Child's status, being 97.5% for Child's A and 64% for Child's B patients. Recurrence of varices occurred in 15% of patients after a mean interval of 19 months. We conclude that endoscopic sclerotherapy is an effective method of treatment for variceal bleeding due to non-cirrhotic portal fibrosis, and is a reasonable alternative to surgery.

MeSH terms

  • Adult
  • Endoscopy
  • Esophageal and Gastric Varices / etiology
  • Esophageal and Gastric Varices / therapy*
  • Female
  • Follow-Up Studies
  • Gastrointestinal Hemorrhage / etiology
  • Gastrointestinal Hemorrhage / therapy*
  • Humans
  • Hypertension, Portal / complications*
  • Male
  • Polidocanol
  • Polyethylene Glycols / therapeutic use*
  • Recurrence
  • Sclerosing Solutions / therapeutic use*
  • Sclerotherapy*
  • Time Factors

Substances

  • Sclerosing Solutions
  • Polidocanol
  • Polyethylene Glycols